Design, synthesis and biological study of hybrid drug candidates of nitric oxide releasing cucurbitacin-inspired estrone analogs for treatment of hepatocellular …
MA Abou-Salim, MA Shaaban, MK Abd El Hameid… - Bioorganic …, 2019 - Elsevier
Abstract Development of hybrid drug candidates is well known strategy for designing
antitumor agents. Herein, a novel class of nitric oxide donating cucurbitacin inspired estrone …
antitumor agents. Herein, a novel class of nitric oxide donating cucurbitacin inspired estrone …
Novel EGFR‐MAPK kinase and ABC transporter inhibitors for HepG2 resistant to Erlotinib
Hepatocellular carcinoma (HCC) is the third‐leading cause of cancer death in the world,
with outlook for most patients having a 5‐year survivability of less than 5%. In a previous …
with outlook for most patients having a 5‐year survivability of less than 5%. In a previous …
[HTML][HTML] Correlation of cancer stem cell markers and immune cell markers in resected non-small cell lung cancer
Z Huang, H Yu, J Zhang, H Jing, W Zhu, X Li… - Journal of …, 2017 - ncbi.nlm.nih.gov
Background: Recent studies confirmed that immunotherapy showed prominent efficacy in
non-small cell lung cancer (NSCLC). Cancer stem cells/cancer initiating cells are resistant to …
non-small cell lung cancer (NSCLC). Cancer stem cells/cancer initiating cells are resistant to …
[HTML][HTML] 肺癌的个体化靶向治疗
南娟 - Chinese Journal of Lung Cancer, 2013 - ncbi.nlm.nih.gov
由于每一肺癌患者在临床特征、 预后、 治疗反应和耐受性方面的进展都是独特的，
所以肺癌被认为是异质性疾病。 个体化用药是指运用标志物来预测哪些患者更易获益于某种 …
所以肺癌被认为是异质性疾病。 个体化用药是指运用标志物来预测哪些患者更易获益于某种 …
Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib
AC Tsai, CY Wang, JP Liou, HC Pai, CJ Hsiao… - Cell Death & …, 2014 - nature.com
Microtubule-binding agents, such as taxanes and vinca alkaloids, are used in the treatment
of cancer. The limitations of these treatments, such as resistance to therapy and the need for …
of cancer. The limitations of these treatments, such as resistance to therapy and the need for …
Squamous-cell transformation in a patient with lung adenocarcinoma receiving erlotinib: Co-occurrence with T790M mutation
DDG Bugano, N Kalhor, J Zhang, M Neskey… - Cancer Treatment …, 2015 - Elsevier
We report on a patient with metastatic lung adenocarcinoma who underwent testing for
EGFR mutations in a pleural effusion that failed to show any alterations and received …
EGFR mutations in a pleural effusion that failed to show any alterations and received …
[HTML][HTML] EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties
Y Shao, H Lv, DS Zhong, QH Zhou - Oncology Letters, 2018 - spandidos-publications.com
Patients with non-small-cell lung cancer (NSCLC) with sensitive epidermal growth factor
receptor (EGFR) mutations generally react well to tyrosine kinase inhibitors (TKIs). However …
receptor (EGFR) mutations generally react well to tyrosine kinase inhibitors (TKIs). However …
Chemoresistance of lung cancer cells: 2D and 3D in vitro models for anticancer drug screening
V Kaushik, JS Yakisich, Y Kulkarni… - Lung Cancer. Strateg …, 2018 - books.google.com
Chemoresistance of lung cancer cells is a key factor that limits the treatment of lung cancer
patients. Patients may initially respond to standard chemotherapy, but this is often followed …
patients. Patients may initially respond to standard chemotherapy, but this is often followed …
An integrative analysis of the putative gefitinib-resistance related genes in a lung cancer cell line model system
X Han, M Liu, S Wang, G Lv, L Ma… - Current Cancer Drug …, 2015 - ingentaconnect.com
The epidermal growth factor receptor-tyrosine kinase inhibitors (EGFRTKI), such as gefitinib
and erlotinib have improved the survival of patients with nonsmall cell lung cancer (NSCLC) …
and erlotinib have improved the survival of patients with nonsmall cell lung cancer (NSCLC) …